Dassault Systèmes announced its investment in Click Therapeutics, a leader in prescription digital therapeutics and software-enhanced drug therapies. The transaction advances Dassault Systèmes’ transformation of the patient experience in life sciences and healthcare through end-to-end technology solutions used across the healthcare ecosystem.
The transaction strengthens the existing relationship between Dassault Systèmes’ MEDIDATA brand and Click Therapeutics, helping to improve patient engagement – post-trial through commercialization – and advancing the Patient Experience to deliver end-to-end technology solutions across the healthcare ecosystem. The continued relationship and subsequent investment will set a gold standard and unified offering for digital and pharmaceutical clinical trials’ design and execution, providing a path to Prescription Digital Therapeutics (PDTs) and Software-Enhanced (SE) product approvals, expanded labels for existing therapeutics, and, ultimately, a novel pipeline for long-term, real-world evidence generation.
MEDIDATA has virtualized clinical research, creating a unified patient experience with integrated technology solutions. This foundation, built on running over 8,000 active studies annually, allows MEDIDATA, together with Click Therapeutics, to extend their commitment to patients into real-world care, fostering improved coordination and outcomes between patients, physicians, caregivers, and life science manufacturers. Click Therapeutics will gain access to Dassault Systèmes’ global presence and expertise, while both companies will provide unparalleled support for developing PDTs and SE products, making them available to patients.
Also Read: Vitamin Angels appoints global health leader Ana Céspedes as Chief Executive Officer
“Digital therapeutics are beginning to transform the way customers think about their future clinical development programs and are providing demonstrable therapeutic benefits over drugs alone in many cases,” said Anthony Costello, CEO, Medidata. “Today’s investment in Click Therapeutics reflects our commitment to this exciting technology, and our partnership with them will enable our customers to take the fastest, most reliable path to bringing digital therapeutics to patients, helping to build a direct connection to patients over a life-long healthcare journey.”
“Since the FDA shared its latest thinking on Prescription Drug Use-Related Software in guidance, we have experienced a surge in interest in how software can add to the benefits of medication. Now is the time to expand treatment options for patients through software as medicine,” said David Benshoof Klein, CEO, Click Therapeutics. “The investment from Dassault Systèmes, the foremost leader in virtualizing the life sciences and healthcare industry, will enable us to continue to expand the boundaries of medicine and develop new, cutting-edge patient solutions to advance care.”
Source: BusinessWire